Effect of empagliflozin alone or combined with low-dose semaglutide on metabolic dysfunction-associated steatohepatitis and type 2 diabetes - a histology-based randomized, placebocontrolled, double-blind phase 4 trial (COMBAT_T2

Conference Reports for NATAP

EASL - European Association
for the Study of the Liver
Barcelona, Spain
May 27-30, 2026


Effect of empagliflozin alone or combined with low-dose semaglutide on metabolic dysfunction-associated steatohepatitis and type 2 diabetes - a histology-based randomized, placebocontrolled, double-blind phase 4 trial (COMBAT_T2_NASH)

	EASL 2026 May 26-30 Barcelona